https://trial.medpath.com/news/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/news/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/news/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/news/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/news/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/news/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9